Cannabis & Opioid Reduction: Evidence from Ohio Patient Surveys

The Lab

Yes—Ohio survey data suggest many patients and consumers believe cannabis can help reduce reliance on prescription painkillers, especially in chronic pain care, but the evidence is still mostly self-reported and does not prove that cannabis will replace opioids for every person. The most accurate takeaway is that cannabis may function as an opioid-sparing option for some Ohio adults when it is used thoughtfully, with realistic expectations and clinical oversight.

What the Ohio surveys actually show

To be precise, the Ohio evidence base mixes patient-focused surveys with one broader Ohio user survey. Even so, the pattern is consistent enough to be worth attention.

Ohio source What it found What it does not prove
Ohio survey In a peer-reviewed survey of 242 Ohio chronic pain patients, 60.7% were current opioid users; among respondents willing to consider medical marijuana, 67.6% said they wanted to use less opioids after starting, and 93.6% said they would follow pain-specialist guidance. This measured attitudes and intended behavior, not verified opioid reduction after cannabis use.
working paper An Ohio State working paper reported that 77.55% of current and potential Ohio medical marijuana patients agreed marijuana reduced their use of prescription painkillers. It is self-reported survey evidence, not a randomized clinical trial.
2025 report Ohio State’s 2025 annual survey of more than 4,000 Ohio marijuana users found 79% agreed marijuana reduced their need for prescription painkillers and 71% said it reduced their need for other prescription drugs. This source is broader than a pure patient survey because it includes recreational users as well as patients and prospective patients.

Taken together, these Ohio sources do not prove causation, but they do show a repeated substitution signal: many Ohio respondents say cannabis either helps them reduce painkiller use or makes them want to try doing so. That signal is strongest in chronic pain discussions, where patients are often searching for alternatives that may reduce dose intensity, side effects, or long-term dependence on prescription opioids.

What broader research says about cannabis versus opioids

The broader literature supports cautious interest, not hype. A 2024 BMJ review comparing cannabis for medical use with opioids for chronic non-cancer pain concluded that cannabis may be similarly effective and may lead to fewer discontinuations due to adverse events. At the same time, a widely cited Annals review found limited evidence that cannabis may help neuropathic pain, but insufficient evidence for many other chronic pain conditions. In other words, cannabis should be framed as a possible tool in pain management—not as a blanket replacement for opioids in every case.

Policy-level evidence is also mixed. A 2021 policy review of U.S. studies found results were “largely inconclusive,” while still noting possible reductions in high-risk opioid prescribing and other opioid-related harms. A separate rapid review summarized studies showing reduced Schedule III opioid prescriptions, dosage, and Medicaid spending after medical cannabis legalization in some settings, but not across all opioid outcomes. That is why we should be careful not to promise more than the evidence can support: the signal is real, but the certainty is still limited.

What these surveys do not mean

Ohio survey findings about opioid reduction are not the same as proof that cannabis treats opioid use disorder. That distinction matters. An NCBI review found no evidence that cannabis improved key opioid use disorder outcomes such as relapse, hospitalization, overdose, functioning, or quality of life. For Ohio residents dealing with opioid dependence or addiction, evidence-based addiction treatment should remain the foundation of care. Cannabis fits more credibly into a discussion about pain management, symptom burden, and possible opioid sparing—not as a replacement for established OUD treatment.

Why this matters for Ohio consumers

For Ohio residents, this is no longer just a policy debate. Under Ohio’s DCC rules, licensed dispensaries can sell cannabis to adults 21 and older, and Ohio’s adult-use sales began on August 6, 2024. That makes product consistency, labeling, dosing, and format choice more important than ever—especially for people trying to move away from a routine built around heavier pharmaceuticals.

At Main Street Health, We believe Ohio adults deserve regulated, well-made products that fit real-world needs. Some people want inhalation-free options. Others prefer capsules, tinctures, topicals, gummies, patches, concentrates, or vape products with more predictable dosing and format control. When the goal is to reduce harm, consistency matters.

Find MSH products in Ohio

If you are an Ohio resident looking for regulated cannabis products, visit Our Where to Buy page to find MSH products near you. Whether you are shopping in Ohio’s adult-use market or participating in the medical program, We are committed to products designed around consistency, quality, and practical patient needs.

SHARE THIS POST